IDEXX Laboratories, Inc. vs iShares MBS ETF — how do they compare? IDEXX Laboratories, Inc. trades at $552.09 (market cap $44.48B), while iShares MBS ETF trades at $93.38. Which is the better fit depends on your goals.
| IDXX | MBB | |
|---|---|---|
Market Cap | $44.48B | — |
Sector | Health | — |
52-Week High | $766.68 | $96.91 |
52-Week Low | $520.87 | $92.92 |
Enterprise Value | $45.38B | — |
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
MBB (iShares MBS ETF) trades at $93.57, down 0.22% on the day, with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings and has upcoming dividend payments. Recent news highlights institutional activity, including Comerica Bank reducing its stake while Concurrent Investment Advisors and Aureum Wealth increased positions in Q4 2026.
The outlook remains cautious due to bearish technical trends and mixed institutional sentiment. Risks include interest rate sensitivity impacting mortgage-backed securities. Opportunities lie in steady dividend income, but investors should monitor Federal Reserve policy shifts for potential volatility in the MBS market.
Trailing returns across standard periods
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →